Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014

Biochemical and Biophysical Research Communications

Volumn 443, Issue 2, 2014, Pages 406-412

  Huo, Hai Zhong ^a   Zhou, Zhi Yuan ^a   Wang, Bing ^a   Qin, Jian ^a   Liu, Wen Yong ^a   Gu, Yan ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Autophagy; AZD 2014; Colorectal cancer; mTOR complexes; Signaling

Indexed keywords

3 METHYLADENINE; AUTOPHAGY PROTEIN 5; AUTOPHAGY PROTEIN 7; AZD 2014; BECLIN 1; HYDROXYCHLOROQUINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; PROTEIN S6; S6 KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS ASSAY; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CELL DEATH; CELL GROWTH; CELL LINE; CELL VIABILITY ASSAY; CLONOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE SILENCING; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

MAMMALIA; MUS;

3-MA; 3-METHYALDENINE; 4E-BP1; AUTOPHAGY; AZD-2014; COLORECTAL CANCER; EUKARYOTIC INITIATION FACTOR 4E-BINDING PROTEIN 1; LC3B; LIGHT CHAIN 3B; MAMMALIAN TARGET OR RAPAMYCIN; MTOR; MTOR COMPLEX 1; MTOR COMPLEX 2; MTOR COMPLEXES; MTORC1; MTORC2; P70-S6 KINASE 1; S6K; SIGNALING;

ANIMALS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; HT29 CELLS; HUMANS; MICE; MICE, SCID; MULTIPROTEIN COMPLEXES; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84892442937     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.11.099     Document Type: Article

References (31)

1. A. Chen, J. Xu, and A.C. Johnson Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1 Oncogene 25 2006 278 287
2. K.M. Mohandas, and D.C. Desai Epidemiology of digestive tract cancers in India. V. Large and small bowel Indian J. Gastroenterol. 18 1999 118 121
3. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics CA Cancer J. Clin. 62 2012 10 29
4. D.M. Gustin, and D.E. Brenner Chemoprevention of colon cancer: current status and future prospects Cancer Metastasis Rev. 21 2002 323 348
5. R. Gorlick, and J.R. Bertino Drug resistance in colon cancer Semin. Oncol. 26 1999 606 611
6. D.B. Longley, W.L. Allen, and P.G. Johnston Drug resistance, predictive markers and pharmacogenomics in colorectal cancer Biochim. Biophys. Acta 1766 2006 184 196
7. D.D. Fang, C.C. Zhang, Y. Gu, J.P. Jani, J. Cao, K. Tsaparikos, J. Yuan, M. Thiel, A. Jackson-Fisher, Q. Zong, P.B. Lappin, T. Hayashi, R.B. Schwab, A. Wong, A. John-Baptiste, S. Bagrodia, G. Los, S. Bender, J. Christensen, and T. Vanarsdale Antitumor efficacy of the dual PI3K/mTOR inhibitor PF-04691502 in a human xenograft tumor model derived from colorectal cancer stem cells harboring a mutation PLoS One 8 2013 e67258
8. A.I. Ekstrand, M. Jonsson, A. Lindblom, A. Borg, and M. Nilbert Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer Fam Cancer 9 2010 125 129
9. F.V. Din, A. Valanciute, V.P. Houde, D. Zibrova, K.A. Green, K. Sakamoto, D.R. Alessi, and M.G. Dunlop Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells Gastroenterology 142 2012 1504 1515 e1503
10. M. Sugiyama, H. Takahashi, K. Hosono, H. Endo, S. Kato, K. Yoneda, Y. Nozaki, K. Fujita, M. Yoneda, K. Wada, H. Nakagama, and A. Nakajima Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway Int. J. Oncol. 34 2009 339 344
11. A. Efeyan, and D.M. Sabatini MTOR and cancer: many loops in one pathway Curr. Opin. Cell Biol. 22 2010 169 176
12. A. Gomez-Pinillos, and A.C. Ferrari MTOR signaling pathway and mTOR inhibitors in cancer therapy Hematol Oncol Clin North Am 26 2012 483 505 vii
13. Y.Y. Zaytseva, J.D. Valentino, P. Gulhati, and B.M. Evers MTOR inhibitors in cancer therapy Cancer Lett. 319 2012 1 7
14. H.Z. Huo, B. Wang, J. Qin, S.Y. Guo, W.Y. Liu, and Y. Gu AMP-activated protein kinase (AMPK)/Ulk1-dependent autophagic pathway contributes to C6 ceramide-induced cytotoxic effects in cultured colorectal cancer HT-29 cells Mol. Cell Biochem. 378 2013 171 181
15. S.Y. Sun MTOR kinase inhibitors as potential cancer therapeutic drugs Cancer Lett. 340 2013 1 8
16. K.G. Pike, K. Malagu, M.G. Hummersone, K.A. Menear, H.M. Duggan, S. Gomez, N.M. Martin, L. Ruston, S.L. Pass, and M. Pass Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014 Bioorg. Med. Chem. Lett. 23 2013 1212 1216
17. P. Boya, R.A. Gonzalez-Polo, N. Casares, J.L. Perfettini, P. Dessen, N. Larochette, D. Metivier, D. Meley, S. Souquere, T. Yoshimori, G. Pierron, P. Codogno, and G. Kroemer Inhibition of macroautophagy triggers apoptosis Mol. Cell Biol. 25 2005 1025 1040
18. E.D. Plowey, S.J. Cherra 3rd, Y.J. Liu, and C.T. Chu Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells J. Neurochem. 105 2008 1048 1056
19. F. Scarlatti, R. Maffei, I. Beau, P. Codogno, and R. Ghidoni Role of non-canonical Beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells Cell Death Differ. 15 2008 1318 1329
20. E.H. Kim, S. Sohn, H.J. Kwon, S.U. Kim, M.J. Kim, S.J. Lee, and K.S. Choi Sodium selenite induces superoxide-mediated mitochondrial damage and subsequent autophagic cell death in malignant glioma cells Cancer Res. 67 2007 6314 6324
21. K. Sommer, S.O. Peters, I.H. Robins, M. Raap, G.J. Wiedemann, S. Remmert, P. Sieg, C. Bittner, and T. Feyerabend A preclinical model for experimental chemotherapy of human head and neck cancer Int. J. Oncol. 18 2001 1145 1149
22. F. Bruzzese, E. Di Gennaro, A. Avallone, S. Pepe, C. Arra, M. Caraglia, P. Tagliaferri, and A. Budillon Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo Clin. Cancer Res. 12 2006 617 625
23. M.W. Craighead, P. Tiwari, R.G. Keynes, and C.M. Waters Human oligodendroglial cell line, MO3.13, can be protected from apoptosis using the general caspase inhibitor zVAD-FMK J. Neurosci. Res. 57 1999 236 243
24. P.O. Seglen, and P.B. Gordon 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes Proc. Natl. Acad. Sci. U. S. A. 79 1982 1889 1892
25. R.K. Amaravadi, and C.B. Thompson The roles of therapy-induced autophagy and necrosis in cancer treatment Clin. Cancer Res. 13 2007 7271 7279
26. G. Juhasz, B. Erdi, M. Sass, and T.P. Neufeld Atg7-dependent autophagy promotes neuronal health, stress tolerance, and longevity but is dispensable for metamorphosis in Drosophila Genes Dev. 21 2007 3061 3066
27. X.H. Liang, S. Jackson, M. Seaman, K. Brown, B. Kempkes, H. Hibshoosh, and B. Levine Induction of autophagy and inhibition of tumorigenesis by Beclin 1 Nature 402 1999 672 676
28. A.Y. Choo, S.O. Yoon, S.G. Kim, P.P. Roux, and J. Blenis Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation Proc. Natl. Acad. Sci. U. S. A. 105 2008 17414 17419
29. D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101
30. D.J. Klionsky, and S.D. Emr Autophagy as a regulated pathway of cellular degradation Science 290 2000 1717 1721
31. D.G. Hardie, F.A. Ross, and S.A. Hawley AMP-activated protein kinase: a target for drugs both ancient and modern Chem. Biol. 19 2012 1222 1236